𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon-α therapy combined with nonsteroid antiinflammatory drugs for treatment of chronic viral hepatitis?

✍ Scribed by Pietro Andreone; Carmela Cursaro; Giovanni Gasbarrini

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
145 KB
Volume
16
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost effectiveness of interferon α2b com
Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
✍ Zobair M. Younossi; Mendel E. Singer; John G. McHutchison; Kenneth M. Shermock 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Treatment of chronic hepatitis C with Interferon (IFN) ␣2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated

Limitation of combination therapy of int
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
✍ Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy a

Treatment of chronic type B hepatitis wi
Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis
✍ Werner-J. Mayet; Georg Hess; Guido Gerken; Siegbert Rossol; Rita Voth; Michael M 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

Recombinant human a-interferon is now under intensive investigation as therapy for chronic Type B hepatitis. Recent reports have suggested that prolonged a- interferon therapy may induce autoimmune reactions. We have evaluated the problem of autoimmunity related to a-interferon therapy by testing fo

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr